|
Number of subjects
|
20
|
27
|
13
|
|
Age (mean ± SD)
|
67 ± 10
|
68 ± 9
|
58 ± 15
|
|
Males, n (%)
|
10 (50)
|
17 (63)
|
6 (46)
|
|
Asthma diagnosis, n (%)
|
3 (15)
|
5 (19)
|
3 (23)
|
|
Spirometry (mean ± SD)
|
|
FEV1 (% of predicted)
|
67 ± 17
|
68 ± 25
|
91 ± 20
|
|
FVC (% of predicted)
|
86 ± 12
|
88 ± 24
|
91 ± 20
|
|
FEV1/FVC
|
59 ± 12
|
56 ± 12
|
78 ± 6
|
|
Smoking status, n(%)
|
|
Current smoker
|
13 (65)
|
7 (26)
|
0
|
|
Former smoker
|
6 (30)
|
18 (67)
|
4 (31)
|
|
Never smoker
|
1 (5)
|
2 (7)
|
9 (69)
|
|
Pack/years in smokers (mean ± SD)
|
44 ± 18
|
43 ± 28
|
8 ± 15
|
|
Treatment at time of review, n (%)
|
|
Antimicrobial therapy
|
0
|
0
|
0
|
|
Inhaled corticosteroid therapy
|
5 (25)
|
11 (41)
|
4 (31)
|
|
Inhaled bronchodilator therapy
|
6 (30)
|
13 (48)
|
4 (31)
|
|
Systemic corticosteroid therapy
|
1 (5)
|
0
|
1 (7)
|
